

Yi-Long Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3716644/publications.pdf>

Version: 2024-02-01

505
papers

67,512
citations

3334

91
h-index

816

246
g-index

537
all docs

537
docs citations

537
times ranked

37768
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib or Carboplatin+Paclitaxel in Pulmonary Adenocarcinoma. <i>New England Journal of Medicine</i> , 2009, 361, 947-957.	27.0	7,606
2	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742.	10.7	3,758
3	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	27.0	3,181
4	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 39-51.	1.1	3,162
5	First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2167-2177.	27.0	2,808
6	Osimertinib or Platinum+Pemetrexed in EGFR T790M-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 629-640.	27.0	2,631
7	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	13.7	2,347
8	Lung cancer: current therapies and new targeted treatments. <i>Lancet</i> , The, 2017, 389, 299-311.	13.7	2,267
9	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	10.7	1,740
10	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	10.7	1,369
11	Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). <i>Journal of Clinical Oncology</i> , 2011, 29, 2866-2874.	1.6	1,368
12	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. <i>Lancet</i> , The, 2008, 372, 1809-1818.	13.7	1,248
13	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. <i>Lancet</i> , The, 2009, 374, 1432-1440.	13.7	1,062
14	Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723.	27.0	1,042
15	Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. <i>Cancer Cell</i> , 2010, 17, 77-88.	16.8	956
16	First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2017, 389, 917-929.	13.7	919
17	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1454-1466.	10.7	877
18	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology</i> , The, 2015, 16, 830-838.	10.7	786

#	ARTICLE	IF	CITATIONS
19	Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3012-3024.	7.0	741
20	The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 990-1003.	1.1	628
21	The International Association for the Study of Lung Cancer Lung Cancer Staging Project. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1675-1684.	1.1	550
22	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1204-1223.	1.1	530
23	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
24	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	1.6	445
25	Global cancer surgery: delivering safe, affordable, and timely cancer surgery. <i>Lancet Oncology</i> , The, 2015, 16, 1193-1224.	10.7	442
26	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
27	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	10.7	436
28	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 3196-3203.	7.0	427
29	Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncology</i> , The, 2014, 15, 489-538.	10.7	411
30	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL). <i>Lancet Oncology</i> , 2016, 17, 1016-1027.	10.7	406
31	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 953-961.	10.7	389
32	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 2244-2250.	1.6	361
33	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018, 36, 2702-2709.	1.6	359
34	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	10.7	353
35	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1109-1121.	1.1	342
36	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 300-311.	1.1	338

#	ARTICLE	IF	CITATIONS
37	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204.	1.6	323
38	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	1.1	323
39	A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. <i>Lung Cancer</i> , 2002, 36, 1-6.	2.0	320
40	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	1.6	308
41	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. <i>Oncimmunology</i> , 2017, 6, e1356145.	4.6	305
42	First-Line Afatinib versus Chemotherapy in Patients with Non-“Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 380-390.	1.1	300
43	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. <i>Molecular Cancer</i> , 2010, 9, 188.	19.2	291
44	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. <i>Nature Genetics</i> , 2012, 44, 1330-1335.	21.4	286
45	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2013, 14, 777-786.	10.7	280
46	Impact of Specific Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i>-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965.	1.6	280
47	Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. <i>Lancet Oncology</i> , The, 2010, 11, 733-740.	10.7	266
48	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	1.1	260
49	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i>-Mutated, MET Factor-“Dysregulated Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3101-3109.	1.6	252
50	Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3316-3321.	1.6	233
51	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411.	1.6	230
52	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i>-Positive Non-“Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	1.6	216
53	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-“Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015, 33, 2660-2666.	1.6	215
54	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 651-665.	1.1	211

#	ARTICLE	IF	CITATIONS
55	Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5080-5087.	1.6	208
56	Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1962-1969.	1.1	208
57	Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. <i>Annals of Oncology</i> , 2018, 29, 945-952.	1.2	197
58	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	196
59	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2235-2245.	1.6	193
60	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	2.0	189
61	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
62	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 639-650.	1.1	182
63	Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. <i>Journal of Thoracic Oncology</i> , 2007, 2, 430-439.	1.1	180
64	Lung Adenocarcinoma Harboring EGFR T790M and In-Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1723-1727.	1.1	174
65	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2112-2119.	1.1	172
66	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 666-680.	1.1	170
67	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlode 10.7 169 8. 1132-1143.	10.7	169
68	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 681-690.	10.7	166
69	Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 707-716.	10.7	159
70	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	1.6	159
71	EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas. <i>Oncologist</i> , 2012, 17, 978-985.	3.7	156
72	Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status. <i>PLoS ONE</i> , 2012, 7, e40109.	2.5	156

#	ARTICLE	IF	CITATIONS
73	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 33-39.	2.0	156
74	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. <i>British Journal of Cancer</i> , 2017, 116, 568-574.	6.4	155
75	Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation. <i>Clinical Cancer Research</i> , 2014, 20, 1383-1392.	7.0	153
76	Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. <i>Nature Communications</i> , 2019, 10, 1772.	12.8	149
77	A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 114, 96-102.	2.0	146
78	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	1.1	146
79	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 4027-4034.	1.6	141
80	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2089-2099.	1.1	139
81	Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1872-1880.	1.1	132
82	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
83	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2100-2111.	1.1	120
84	Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 521-532.	1.1	119
85	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. <i>Journal of Thoracic Oncology</i> , 2013, 8, 373-384.	1.1	113
86	Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. <i>Cancer Letters</i> , 2008, 265, 307-317.	7.2	112
87	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1668-1675.	1.1	111
88	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	17.0	111
89	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK-wild-type advanced non-small cell lung cancer. , 2020, 8, e000376.		111
90	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1912-1923.	1.1	105

#	ARTICLE	IF	CITATIONS
91	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase ⁺ Positive Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1617.	7.1	105
92	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	6.2	101
93	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 681-692.	1.1	101
94	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1745-1753.	1.1	100
95	Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 2009, 15, 651-658.	1.9	99
96	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. <i>Cancer Cell</i> , 2021, 39, 1279-1291.e3.	16.8	99
97	Distribution and prognosis of uncommon metastases from non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 149.	2.6	96
98	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum+pemetrexed for T790M mutation ⁺ positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 373-380.	4.1	95
99	Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 60, 102990.	6.1	95
100	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	2.9	90
101	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	1.1	89
102	PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. <i>Oncolmmunology</i> , 2017, 6, e1284722.	4.6	87
103	Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 209-219.	10.7	87
104	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. <i>Nature Communications</i> , 2016, 7, 11843.	12.8	86
105	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
106	Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network. <i>Oncologist</i> , 2019, 24, 1159-1165.	3.7	85
107	Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 1690-1701.	9.4	84
108	Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055). <i>Cancer Research</i> , 2012, 72, 1804-1813.	0.9	81

#	ARTICLE	IF	CITATIONS
109	ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. <i>Clinical Lung Cancer</i> , 2018, 19, e533-e536.	2.6	80
110	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1368-1375.	1.1	79
111	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. <i>Tumor Biology</i> , 2016, 37, 4251-4261.	1.8	78
112	Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 5480-5488.	7.0	78
113	EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 887-903.	8.7	76
114	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185.	6.4	76
115	INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2011, 11, 430.	2.6	74
116	Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. <i>Journal of Translational Medicine</i> , 2013, 11, 168.	4.4	74
117	Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8511-8511.	1.6	74
118	KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1381-1388.	1.5	73
119	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. <i>International Journal of Cancer</i> , 2015, 137, 311-319.	5.1	72
120	Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. <i>Journal of Hematology and Oncology</i> , 2015, 8, 54.	17.0	71
121	Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. <i>Journal of Hematology and Oncology</i> , 2017, 10, 68.	17.0	70
122	Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 924-932.	1.1	70
123	Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4929-4937.	7.0	67
124	Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK-Rearrangement. <i>Journal of Thoracic Oncology</i> , 2019, 14, 726-731.	1.1	67
125	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487.	1.2	67
126	Retrospective Analysis of Prognostic Factors in 205 Patients with Laryngeal Squamous Cell Carcinoma Who Underwent Surgical Treatment. <i>PLoS ONE</i> , 2013, 8, e60157.	2.5	66

#	ARTICLE	IF	CITATIONS
127	In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 637-646.	2.3	63
128	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. <i>Lung Cancer</i> , 2018, 125, 86-92.	2.0	63
129	Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. <i>Cancer</i> , 2015, 121, 3069-3079.	4.1	62
130	Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2017, 61, 70-81.	7.7	62
131	Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 34, 187-195.	1.4	61
132	The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2082-2088.	1.1	61
133	The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1503-1510.	1.1	61
134	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer: KEYNOTE-042 China Study. <i>International Journal of Cancer</i> , 2021, 148, 2313-2320.	5.1	60
135	Multiple primary malignancies involving lung cancer. <i>BMC Cancer</i> , 2015, 15, 696.	2.6	57
136	Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. <i>Clinical Lung Cancer</i> , 2016, 17, 223-231.	2.6	57
137	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. <i>MAbs</i> , 2018, 10, 1301-1311.	5.2	57
138	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Drugs</i> , 2021, 81, 257-266.	10.9	57
139	Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0149370.	2.5	57
140	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479.	2.6	56
141	Osimertinib as adjuvant therapy in patients (pts) with stage IB-III A EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA5-LBA5.	1.6	56
142	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. , 2022, 10, e003534.		56
143	Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials. <i>Lung Cancer</i> , 2014, 85, 66-73.	2.0	55
144	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 883-889.	1.1	55

#	ARTICLE	IF	CITATIONS
145	EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1415-1421.	1.1	53
146	A comparative study of the risk factors for lung cancer in Guangdong, China. <i>Lung Cancer</i> , 1996, 14, S99-S105.	2.0	52
147	Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO) Tj ETQq1 1 0.284314 rg5T /Over	1.1	51
148	The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 71358-71370.	1.8	51
149	The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). <i>Journal of Thoracic Oncology</i> , 2019, 14, 503-512.	1.1	51
150	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. <i>Human Molecular Genetics</i> , 2016, 26, ddw414.	2.9	50
151	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. <i>Human Molecular Genetics</i> , 2016, 25, 620-629.	2.9	50
152	The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 167.	17.0	50
153	Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 691-700.	3.0	50
154	Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 250-258.	1.1	49
155	BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. <i>Molecular Cancer</i> , 2013, 12, 61.	19.2	48
156	Genomic signatures define three subtypes of EGFR-mutant stage III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021, 12, 6450.	12.8	48
157	Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis. <i>Lung Cancer</i> , 2014, 85, 230-238.	2.0	47
158	The changing landscape of clinical trial and approval processes in China. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 577-583.	27.6	46
159	Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e49-e53.	1.1	46
160	The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 659-665.	2.5	45
161	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study. <i>Lung Cancer</i> , 2013, 81, 280-287.	2.0	44
162	Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. <i>Lung Cancer: Targets and Therapy</i> , 2014, 5, 1.	2.7	44

#	ARTICLE	IF	CITATIONS
163	EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2012, 83, 248-256.	1.9	43
164	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). <i>Lung Cancer</i> , 2014, 83, 174-181.	2.0	43
165	Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 85-96.	1.1	43
166	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i> -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3593-3602.	1.6	43
167	Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 232-243.	1.1	42
168	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 136.	17.0	42
169	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	1.4	42
170	ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	2.4	42
171	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. <i>Biomarker Research</i> , 2020, 8, 19.	6.8	42
172	Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e69104.	2.5	42
173	miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 11637-11650.	1.8	42
174	The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. <i>European Journal of Pharmacology</i> , 2007, 570, 175-181.	3.5	41
175	A family history of cancer and lung cancer risk in never-smokers: A clinic-based case-control study. <i>Lung Cancer</i> , 2015, 89, 94-98.	2.0	41
176	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. <i>Journal of Hematology and Oncology</i> , 2016, 9, 86.	17.0	41
177	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , 2017, 104, 119-125.	2.0	41
178	The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer. <i>Chest</i> , 2019, 155, 502-509.	0.8	41
179	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2021, 39, 477-487.	2.6	41
180	Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2017, 22, 61-69.	3.7	40

#	ARTICLE	IF	CITATIONS
181	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	1.1	40
182	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , 2018, 126, 1-8.	2.0	40
183	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	2.0	40
184	Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 707-716.	2.3	39
185	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1355-1364.	4.1	39
186	Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2279-2290.	1.9	39
187	Timing and Origins of Local and Distant Metastases in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1136-1148.	1.1	39
188	Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. <i>Oncogene</i> , 2021, 40, 1476-1489.	5.9	39
189	CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9005-9005.	1.6	39
190	HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. <i>Pathology Research and Practice</i> , 2011, 207, 1-7.	2.3	38
191	Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1663666.	12.2	38
192	Insulin-Like Growth Factor-1 Restores Erectile Function in Aged Rats: Modulation the Integrity of Smooth Muscle and Nitric Oxide-Cyclic Guanosine Monophosphate Signaling Activity. <i>Journal of Sexual Medicine</i> , 2008, 5, 1345-1354.	0.6	37
193	Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients. <i>Oncotarget</i> , 2017, 8, 111246-111257.	1.8	37
194	Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. <i>Biomarker Research</i> , 2020, 8, 22.	6.8	37
195	Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. <i>Annals of Oncology</i> , 2021, 32, 85-96.	1.2	37
196	Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 441-447.	2.6	35
197	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. , 2020, 8, e000381.		35
198	The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 51311-51319.	1.8	35

#	ARTICLE	IF	CITATIONS
199	Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 82-93.	2.8	35
200	Use of Bipolar Energy for Transurethral Resection of Superficial Bladder Tumors: Long-Term Results. <i>Journal of Endourology</i> , 2008, 22, 545-550.	2.1	34
201	Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study. <i>Lung Cancer</i> , 2012, 77, 339-345.	2.0	34
202	Novel agents and strategies for overcoming EGFR TKIs resistance. <i>Experimental Hematology and Oncology</i> , 2014, 3, 2.	5.0	34
203	Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA). <i>Human Genetics</i> , 2015, 134, 333-341.	3.8	34
204	Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1609-1615.	1.1	33
205	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 126, 133-138.	2.0	33
206	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. <i>Lung Cancer</i> , 2020, 139, 118-123.	2.0	33
207	RRM1 single nucleotide polymorphism -37Câ†’A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. <i>Journal of Hematology and Oncology</i> , 2010, 3, 10.	17.0	32
208	Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. <i>Lung Cancer</i> , 2011, 74, 274-279.	2.0	32
209	Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 37.	17.0	32
210	Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development. <i>Clinical Chemistry</i> , 2004, 50, 1036-1042.	3.2	31
211	Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. <i>Human Pathology</i> , 2008, 39, 1792-1801.	2.0	31
212	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 401-407.	2.0	31
213	Osimertinib in <i>EGFR</i> T790Mâ€“Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1992-1994.	27.0	31
214	Predictive and Prognostic Potential of TP53 in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). <i>Clinical Lung Cancer</i> , 2021, 22, 100-109.e3.	2.6	31
215	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <i>EGFR</i>-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8017-8017.	1.6	31
216	Clinical outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> mutation, <i>ALK</i> rearrangement and <i>EGFR</i>/<i>ALK</i> co-alterations. <i>Oncotarget</i> , 2016, 7, 65185-65195.	1.8	31

#	ARTICLE	IF	CITATIONS
217	CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. <i>European Journal of Cancer</i> , 2011, 47, 1962-1970.	2.8	30
218	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. <i>Journal of Hematology and Oncology</i> , 2011, 4, 5.	17.0	30
219	Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. <i>EBioMedicine</i> , 2019, 43, 180-187.	6.1	30
220	Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9020-9020.	1.6	30
221	INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i><i>MET</i></i> -amplified NSCLC and first-line osimertinib resistance. <i>Future Oncology</i> , 2022, 18, 1039-1054.	2.4	30
222	MET Expression Plays Differing Roles in Nonâ€œSmall-Cell Lung Cancer Patients with or without EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2014, 9, 725-728.	1.1	29
223	Comparison of threeâ€œdimensional and twoâ€œdimensional visualization in videoâ€œassisted thoracoscopic lobectomy. <i>Thoracic Cancer</i> , 2016, 7, 530-534.	1.9	28
224	A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). <i>BMC Cancer</i> , 2017, 17, 462.	2.6	28
225	Mutational landscape and characteristics of <i><scp>ERBB2</scp></i> in <i><scp>nonâ€œsmall</scp></i> cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1512-1521.	1.9	28
226	MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. <i>Experimental Hematology and Oncology</i> , 2021, 10, 52.	5.0	28
227	Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 2013, 19, 833-838.	1.9	27
228	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. <i>Cancer Letters</i> , 2017, 403, 186-194.	7.2	27
229	Effects of dose modifications on the safety and efficacy of dacomitinib for <i><i>EGFR</i></i> mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2795-2805.	2.4	27
230	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131.	2.0	26
231	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9027-9027.	1.6	26
232	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? – A literature-based meta-analysis. <i>Journal of Hematology and Oncology</i> , 2012, 5, 62.	17.0	25
233	Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 914-919.	1.4	25
234	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19.	2.0	25

#	ARTICLE	IF	CITATIONS
235	Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 567-573.	1.1	25
236	Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of non-small cell lung carcinoma. <i>Cancer</i> , 2006, 106, 146-155.	4.1	24
237	Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (SAiL) Study. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1092-1097.	1.1	24
238	Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. <i>Lung Cancer</i> , 2017, 114, 90-95.	2.0	24
239	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 752-765.	1.1	24
240	Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 109-117.	3.3	24
241	Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. <i>Medical Oncology</i> , 2012, 29, 627-632.	2.5	23
242	Cancer drug development in China: recent advances and future challenges. <i>Drug Discovery Today</i> , 2015, 20, 766-771.	6.4	23
243	Effects of epidermal growth factor receptor tyrosine kinase inhibitors alone on EGFR mutant non-small cell lung cancer with brain metastasis. <i>Thoracic Cancer</i> , 2016, 7, 648-654.	1.9	23
244	DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. <i>Onc Immunology</i> , 2019, 8, e1509173.	4.6	23
245	The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2009, 9, 144.	2.6	22
246	Reviewing the safety of erlotinib in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 147-157.	2.4	22
247	Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2011, 4, 3.	17.0	22
248	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , 2018, 18, 1171.	2.6	22
249	Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy. <i>Tumor Biology</i> , 2013, 34, 33-38.	1.8	21
250	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8575-8587.	2.0	21
251	Application of indocyanine green fluorescence for precision sublobar resection. <i>Thoracic Cancer</i> , 2019, 10, 624-630.	1.9	21
252	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 432-439.	1.3	21

#	ARTICLE	IF	CITATIONS
253	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 596937.	2.8	21
254	Multimomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. , 2021, 9, e002312.		21
255	Clinical trials and biomarker research on lung cancer in China. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S45-S50.	3.4	20
256	Involvement of discoidin domain 1 receptor in recurrence of hepatocellular carcinoma by genome-wide analysis. <i>Medical Oncology</i> , 2012, 29, 3077-3082.	2.5	20
257	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018, 11, 131-141.	2.7	20
258	Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e95-e99.	1.1	20
259	Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 555-562.	2.5	19
260	Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review. <i>Clinical Lung Cancer</i> , 2015, 16, e5-e9.	2.6	19
261	Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. <i>Supportive Care in Cancer</i> , 2015, 23, 635-641.	2.2	19
262	Acute esophagitis for patients with localâ€“regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 465-470.	0.6	19
263	Managing Pain in Patients With Cancer: The Chinese Good Pain Management Experience. <i>Journal of Global Oncology</i> , 2017, 3, 583-595.	0.5	19
264	Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives. <i>Cancer Letters</i> , 2019, 459, 240-247.	7.2	19
265	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	1.1	19
266	Supracricoid partial laryngectomy cricohyoidoepiglottopexy (SCPL-CHEP) versus vertical partial laryngectomy for the treatment of glottic carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 1027-1034.	1.6	18
267	Lung Cancer Treatment Disparities in China: A Question in Need of an Answer. <i>Oncologist</i> , 2014, 19, 1084-1090.	3.7	18
268	Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. <i>Clinical and Translational Oncology</i> , 2014, 16, 463-468.	2.4	18
269	Targeting the MET pathway for potential treatment of NSCLC. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 663-674.	3.4	18
270	Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2016, 98, 1-8.	2.0	18

#	ARTICLE	IF	CITATIONS
271	Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review. <i>Journal of Hematology and Oncology</i> , 2017, 10, 147.	17.0	18
272	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1093-1103.	1.9	18
273	A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. <i>Lung Cancer</i> , 2019, 131, 134-138.	2.0	18
274	Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases. <i>International Journal of Clinical Oncology</i> , 2020, 25, 267-273.	2.2	18
275	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185.	2.0	18
276	Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2009, 27, CRA8000-CRA8000.	1.6	18
277	A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).. <i>Journal of Clinical Oncology</i> , 2011, 29, 7522-7522.	1.6	18
278	KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 635-642.	2.5	17
279	Lung Cancer Working Group Report. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i7-i12.	1.3	17
280	Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. <i>Lung Cancer</i> , 2014, 86, 219-224.	2.0	17
281	Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 375-380.	2.0	17
282	Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 256-264.	2.6	17
283	Visceral pleural invasion in T1 tumors (≥ 3 cm), particularly T1a, in the eighth tumor-node-metastasis classification system for non-small cell lung cancer: a population-based study. <i>Journal of Thoracic Disease</i> , 2019, 11, 2754-2762.	1.4	17
284	Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 68-77.	2.4	17
285	Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 6185-6194.	1.1	17
286	Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2015, 7, 1181-8.	1.4	17
287	Predictive value of TCR V β 2-J β 2 profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. <i>JCI Insight</i> , 2022, 7, .	5.0	17
288	A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG) Tj ETQq0 0 0 rg20/Overlap 10 Tf 50		

#	ARTICLE	IF	CITATIONS
289	Emerging paradigms in targeted treatments for Asian patients with NSCLC. Expert Opinion on Pharmacotherapy, 2015, 16, 1167-1176.	1.8	16
290	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Expert Opinion on Pharmacotherapy, 2016, 17, 1693-1701.	1.8	16
291	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. Cancer Biology and Medicine, 2019, 16, 189.	3.0	16
292	Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection. Annals of Thoracic Surgery, 2020, 109, 1040-1046.	1.3	16
293	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.	2.9	15
294	Detecting the spectrum of multiplex gene mutations in non-small cell lung cancer by Snapshot assay. Chinese Journal of Cancer, 2014, 33, 346-50.	4.9	15
295	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. Journal of Thoracic Oncology, 2022, 17, 816-826.	1.1	15
296	Perioperative targeted therapy for oncogene-driven NSCLC. Lung Cancer, 2022, 172, 160-169.	2.0	15
297	Three cases of severe hepatic impairment caused by erlotinib. British Journal of Clinical Pharmacology, 2009, 68, 464-467.	2.4	14
298	A Clinical Model to Estimate the Pretest Probability of Lung Cancer, Based on 1198 Pedigrees in China. Journal of Thoracic Oncology, 2012, 7, 1534-1540.	1.1	14
299	Prophylactic airway extraction strategy after thoroscopic wedge resection. Thoracic Cancer, 2018, 9, 1406-1412.	1.9	14
300	Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Cancer Treatment Reviews, 2021, 95, 102173.	7.7	14
301	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011). Journal of Thoracic Disease, 2012, 4, 88-101.	1.4	14
302	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	7.0	14
303	A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. BMC Cancer, 2014, 14, 684.	2.6	13
304	Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 85-91.	2.6	13
305	Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. Journal of Thoracic Disease, 2017, 9, 4821-4824.	1.4	13
306	Toward innovative combinational immunotherapy: A systems biology perspective. Cancer Treatment Reviews, 2018, 68, 1-8.	7.7	13

#	ARTICLE	IF	CITATIONS
307	Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. <i>BMC Cancer</i> , 2019, 19, 369.	2.6	13
308	A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). <i>European Journal of Cancer</i> , 2019, 109, 183-191.	2.8	13
309	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 346-352.	1.9	13
310	Quantitative multiplex immunofluorescence analysis identifies infiltrating CD8 ⁺ and CD8 ⁺ T cells as predictive of response to neoadjuvant chemotherapy in breast cancer. <i>Thoracic Cancer</i> , 2020, 11, 2941-2954.	1.9	13
311	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 589-599.	2.4	13
312	Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion. <i>Chest</i> , 2021, 160, 754-764.	0.8	13
313	The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma. <i>Journal of Thoracic Disease</i> , 2015, 7, 1630-6.	1.4	13
314	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. <i>Nature Medicine</i> , 2022, 28, 620-626.	30.7	13
315	An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer. <i>Immunological Investigations</i> , 2009, 38, 665-680.	2.0	12
316	Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 226-230.	1.8	12
317	Do-not-resuscitate orders among advanced-stage Chinese lung cancer patients who died in hospital. <i>Supportive Care in Cancer</i> , 2016, 24, 1763-1769.	2.2	12
318	Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1143-1145.	1.6	12
319	Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases. <i>JAMA Network Open</i> , 2020, 3, e209077.	5.9	12
320	Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. <i>Environment International</i> , 2021, 147, 105975.	10.0	12
321	Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 805-815.e3.	0.8	12
322	High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2013, 13, 37-47.	1.7	11
323	Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. <i>Oncotargets and Therapy</i> , 2015, 8, 999.	2.0	11
324	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). <i>Lung Cancer</i> , 2016, 99, 94-101.	2.0	11

#	ARTICLE	IF	CITATIONS
325	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, e103-e112.	2.6	11
326	Down-“regulation of p16 and <sc>MGMT</sc> promotes the anti-“proliferative and pro-“apoptotic effects of 5-“A</sc>“C</sc> and radiation on cervical cancer cells. <i>Cell Biochemistry and Function</i> , 2017, 35, 488-496.	2.9	11
327	Management of common adverse events related to first-line dacomitinib use in <i>EGFR</i> mutation-positive non-small-cell lung cancer: a pooled safety analysis. <i>Future Oncology</i> , 2019, 15, 1481-1491.	2.4	11
328	Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People-“s Republic of China. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100053.	1.1	11
329	Clinical outcomes of non-“small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. <i>European Journal of Cancer</i> , 2021, 150, 23-30.	2.8	11
330	Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-“positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8105-TPS8105.	1.6	11
331	Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. <i>Journal of Thoracic Disease</i> , 2015, 7, 1205-12.	1.4	11
332	Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1393-1402.	4.2	11
333	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100257.	1.1	11
334	KDR and Sema3 genes expression in bone marrow stromal cells and hematopoietic cells from leukemia patients and normal individuals. <i>Hematology</i> , 2005, 10, 307-312.	1.5	10
335	Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad. <i>Journal of Thoracic Oncology</i> , 2009, 4, 751-752.	1.1	10
336	Novel targeted agents for the treatment of lung cancer in China. <i>Cancer</i> , 2015, 121, 3089-3096.	4.1	10
337	Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT. <i>Medicine (United States)</i> , 2015, 94, e1863.	1.0	10
338	Intraoperative frozen sections of the regional lymph nodes contribute to surgical decision-making in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2016, 8, 1974-1980.	1.4	10
339	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. <i>Lung Cancer</i> , 2019, 130, 18-24.	2.0	10
340	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2008-2015.	2.8	10
341	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-“small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	2.0	10
342	Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 3808-3818.	1.5	10

#	ARTICLE	IF	CITATIONS
343	Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Males, Smokers, and Non-adenocarcinoma Lung Cancer in Patients with EGFR Mutations. <i>International Journal of Biological Markers</i> , 2013, 28, 249-258.	1.8	9
344	Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 81369-81376.	1.8	9
345	Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets. <i>Clinical Lung Cancer</i> , 2022, 23, 135-142.	2.6	9
346	Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9004-9004.	1.6	9
347	Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 39535-39543.	1.8	9
348	Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 339-347.	2.2	9
349	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	7.0	9
350	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.	1.1	9
351	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	2.0	9
352	Clinical outcomes of EGFR+MET vs. EGFR+MET-untreated patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1619-1630.	1.9	9
353	Higher Expression of mRNA and Protein of Insulin-Like Growth Factor Binding Protein-3 in Old Rat Penile Tissues: Implications for Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2011, 8, 2181-2190.	0.6	8
354	Nedaplatin/gemcitabine versus carboplatin/gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 97-102.	2.2	8
355	Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy. <i>Cancer Gene Therapy</i> , 2014, 21, 110-114.	4.6	8
356	The Association between Distal Findings and Proximal Colorectal Neoplasia: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1234-1245.	0.4	8
357	Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation. <i>Thoracic Cancer</i> , 2017, 8, 51-53.	1.9	8
358	Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. <i>Future Oncology</i> , 2019, 15, 2769-2777.	2.4	8
359	Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 4125-4136.	1.4	8
360	High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2564-2573.	1.9	8

#	ARTICLE	IF	CITATIONS
361	A phase II cluster study of single agent ALIY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, TPS8122-TPS8122.	1.6	8
362	The role of T790M mutation in EGFR-TKI re-challenge for patients with <i>EGFR</i> -mutant advanced lung adenocarcinoma. Oncotarget, 2017, 8, 4994-5002.	1.8	8
363	Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives. Cancer Communications, 2021, 41, 1252-1256.	9.2	8
364	Poor prognosis of intra-tumoural TRBV6 variants in <i>EGFR</i> -mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial. Clinical and Translational Medicine, 2022, 12, e775.	4.0	8
365	Toward a cure for lung cancer: important advances in operable non-small cell lung cancer. Science Bulletin, 2022, 67, 1402-1405.	9.0	8
366	Single Nucleotide Polymorphisms in VT11A Gene Contribute to the Susceptibility of Chinese Population to Non-Small Cell Lung cancer. International Journal of Biological Markers, 2015, 30, 286-293.	1.8	7
367	Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers. Lung Cancer, 2015, 90, 205-211.	2.0	7
368	Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value. Journal of Global Oncology, 2017, 3, 285-288.	0.5	7
369	Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib. Journal of Thoracic Oncology, 2019, 14, e81-e82.	1.1	7
370	Biomarker for personalized immunotherapy. Translational Lung Cancer Research, 2019, 8, S308-S317.	2.8	7
371	Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR mutant advanced NSCLC than BIM deletion polymorphism. Clinical and Translational Medicine, 2020, 10, 337-345.	4.0	7
372	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Thoracic Cancer, 2021, 12, 1469-1488.	1.9	7
373	Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 288-292.	0.8	7
374	Phase 3 study of first-line crizotinib vs pemetrexed+cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i> + advanced non-squamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9058-9058.	1.6	7
375	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	2.8	7
376	Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial. Chinese Medical Journal, 2007, 120, 458-462.	2.3	6
377	Genetic Evolution of Epidermal Growth Factor Receptor in Adenocarcinoma With a Bronchioloalveolar Carcinoma Component. Clinical Lung Cancer, 2010, 11, 160-168.	2.6	6
378	Immunotherapy for small-cell lung cancer. Lancet Oncology, The, 2016, 17, 846-847.	10.7	6

#	ARTICLE	IF	CITATIONS
379	Emerging challenges of advanced squamous cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000129.	4.5	6
380	CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. <i>Frontiers in Immunology</i> , 2017, 8, 1713.	4.8	6
381	Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, e234-e236.	1.1	6
382	Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1051.	2.6	6
383	The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge. <i>Science Bulletin</i> , 2019, 64, 499-503.	9.0	6
384	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , 2021, 11, 709877.	2.8	6
385	Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20501-e20501.	1.6	6
386	Research and Standard Care: Lung Cancer in China. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 432-436.	3.8	6
387	A three-dimensional printing navigational template combined with mixed reality technique for localizing pulmonary nodules. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 552-559.	1.1	6
388	What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 217-220.	1.6	6
389	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	3.6	6
390	Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: A case report and review of the literature. <i>Thoracic Cancer</i> , 2012, 3, 84-87.	1.9	5
391	Insight into early-phase trials for lung cancer in the United States. <i>Chinese Journal of Cancer</i> , 2015, 34, 288-94.	4.9	5
392	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 380-387.	1.1	5
393	Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. <i>Chinese Journal of Cancer</i> , 2017, 36, 53.	4.9	5
394	Osimertinib in first line setting: preventive or delayed T790M occurrence?. <i>Translational Lung Cancer Research</i> , 2018, 7, S187-S190.	2.8	5
395	An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or Medicine. <i>Science Bulletin</i> , 2018, 63, 1608-1610.	9.0	5
396	The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2019, 20, 889-891.	10.7	5

#	ARTICLE	IF	CITATIONS
397	TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 144-154.	2.8	5
398	Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage IIâ€“III A (N1â€“N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. <i>Lung Cancer</i> , 2020, 150, 164-171.	2.0	5
399	3-dimensional printed navigational template for localizing small pulmonary nodules: A caseâ€“controlled study. <i>Thoracic Cancer</i> , 2020, 11, 2690-2697.	1.9	5
400	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2021, 154, 113-117.	2.0	5
401	Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2009, 27, CRA8000-CRA8000.	1.6	5
402	SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21689-e21689.	1.6	5
403	What is the significance of TP53 and KRAS mutation for immunotherapy in non-small cell lung cancer?. <i>Translational Cancer Research</i> , 2017, 6, S1115-S1117.	1.0	5
404	From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel. <i>Translational Lung Cancer Research</i> , 2016, 5, 377-388.	2.8	5
405	Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?. <i>Journal of Thoracic Disease</i> , 2013, 5, E93-7.	1.4	5
406	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	2.8	5
407	Post-operative staging and survival based on the revised tnm staging system for non-small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2000, 12, 278-281.	2.2	4
408	Clinical research of lung cancer in China. <i>Chinese-German Journal of Clinical Oncology</i> , 2002, 1, 132-134.	0.1	4
409	Feasibility of computed tomographyâ€“guided core needle biopsy in producing stateâ€“ofâ€“theâ€“art clinical management in Chinese lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 155-161.	1.9	4
410	Right upper lobectomy performed as dividing posterior ascending artery-bronchus-pulmonary vessels is alternative to primary indolent scar carcinomas. <i>Journal of Thoracic Disease</i> , 2016, 8, 1340-1344.	1.4	4
411	Polymorphism of Rs9387478 Correlates with Overall Survival in Female Nonsmoking Patients with Lung Cancer. <i>International Journal of Biological Markers</i> , 2016, 31, 144-152.	1.8	4
412	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 471-481.	4.2	4
413	Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study. <i>Lung Cancer</i> , 2020, 150, 97-106.	2.0	4
414	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 5822-5832.	1.4	4

#	ARTICLE	IF	CITATIONS
415	Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees. <i>BMC Cancer</i> , 2020, 20, 1209.	2.6	4
416	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100297.	1.7	4
417	Ceritinib Efficacy and Safety in Treatment-Naïve Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100131.	1.1	4
418	Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2021, 10, 1711-1719.	2.8	4
419	The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8072-8072.	1.6	4
420	Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8561-8561.	1.6	4
421	A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology. <i>Translational Cancer Research</i> , 2017, 6, S292-S295.	1.0	4
422	Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score. <i>Translational Oncology</i> , 2022, 15, 101254.	3.7	4
423	Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. <i>Cancer Biology and Medicine</i> , 2016, 13, 68-76.	3.0	4
424	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705). <i>Clinical Lung Cancer</i> , 2022, 23, e395-e399.	2.6	4
425	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nsclc in Profile 1014. <i>Annals of Oncology</i> , 2014, 25, v2.	1.2	3
426	Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. <i>Journal of Genetics and Genomics</i> , 2015, 42, 579-587.	3.9	3
427	Surgery in oligometastatic NSCLC patients in the targeted therapy era. <i>Lung Cancer Management</i> , 2016, 5, 141-153.	1.5	3
428	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	4.5	3
429	Dacomitinib in NSCLC: a positive trial with little clinical impact – Authors' reply. <i>Lancet Oncology</i> , 2018, 19, e5.	10.7	3
430	Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12539-12547.	2.0	3
431	Cancer treatment in the coronavirus disease pandemic. <i>Lung Cancer</i> , 2021, 152, 98-103.	2.0	3
432	Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 62 Tc</i> 338-338.	1.7	3

#	ARTICLE	IF	CITATIONS
433	The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. <i>Translational Lung Cancer Research</i> , 2021, 10, 3594-3607.	2.8	3
434	Precise resection of multiple pulmonary nodules using a three-dimensional reconstruction model: A case report. <i>Thoracic Cancer</i> , 2021, 12, 970-973.	1.9	3
435	ZD1839 for the treatment of heavily pretreated non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 7341-7341.	1.6	3
436	eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9115-TPS9115.	1.6	3
437	Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8090-8090.	1.6	3
438	Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, <i>EGFR</i>-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
439	Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases. <i>BMC Medicine</i> , 2022, 20, .	5.5	3
440	Cancer management can be personalized? â€” Cancer genomic research in China. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 156-158.	0.1	2
441	Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? â€” Authors' reply. <i>Lancet Oncology</i> , The, 2013, 14, e438-e439.	10.7	2
442	Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report. <i>Oncology Letters</i> , 2014, 8, 2624-2626.	1.8	2
443	Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study. <i>World Journal of Surgical Oncology</i> , 2017, 15, 12.	1.9	2
444	Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer â€” Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e127.	10.7	2
445	Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial. <i>Lung Cancer</i> , 2018, 115, 121-126.	2.0	2
446	Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). <i>Lung Cancer</i> , 2018, 123, 7-13.	2.0	2
447	Afatinib for the first-line treatment of <i>EGFR</i> mutation-positive NSCLC in China: a review of clinical data. <i>Future Oncology</i> , 2020, 16, 2569-2586.	2.4	2
448	Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1568.	2.8	2
449	Short-term outcome of neoadjuvant immunotherapy and chemotherapy in nonâ€”small cell lung cancer: A systematic review and meta-analysis. <i>JTCVS Open</i> , 2021, , .	0.5	2
450	Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1627-1631.	1.1	2

#	ARTICLE	IF	CITATIONS
451	Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitorâ€œFailed Leptomeningeal Metastases?. <i>Journal of Thoracic Oncology</i> , 2021, 16, e82-e84.	1.1	2
452	Identification of leptomeningeal metastasis-specific exosomal miRNA signature in cerebrospinal fluid of non-small-cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21024-e21024.	1.6	2
453	Clinical trials for lung cancer in China. <i>Translational Lung Cancer Research</i> , 2014, 3, 311-6.	2.8	2
454	The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20502-e20502.	1.6	2
455	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. <i>Lung Cancer</i> , 2022, 163, 14-18.	2.0	2
456	Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 111-126.	2.4	2
457	Clinical trials in lung cancer surgery and research cooperation. <i>Chinese Clinical Oncology</i> , 2014, 3, 46.	1.2	2
458	Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 495-499.	0.1	1
459	Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?. <i>Nuclear Medicine Communications</i> . 2011, 32, 1113-1120.	1.1	1
460	Gene fusions in non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 283-292.	1.5	1
461	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. <i>Lung Cancer Management</i> , 2014, 3, 175-190.	1.5	1
462	IMPRESS is impressive. <i>Lung Cancer Management</i> , 2015, 4, 51-53.	1.5	1
463	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 143-155.	3.1	1
464	BRAIN study: it is hard to draw a conclusion â€œ Authors' reply. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, e34.	10.7	1
465	Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer. <i>Chinese Medical Journal</i> , 2017, 130, 1446-1453.	2.3	1
466	Uniportal video-assisted thoracoscopic surgery left upper lobectomy and systematic lymph node dissection with fused fissure. <i>Journal of Thoracic Disease</i> , 2017, 9, 1375-1381.	1.4	1
467	Systemic tunnel dissection of mediastinal lymph nodes without clamping via uniportal video-assisted thoracoscopic surgery. <i>Journal of Thoracic Disease</i> , 2017, 9, 3272-3274.	1.4	1
468	Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer. <i>Journal of Cancer</i> , 2018, 9, 2987-2993.	2.5	1

#	ARTICLE	IF	CITATIONS
469	<p>Familial association of lung cancer with liver cancer in first-degree relatives</p>. Cancer Management and Research, 2019, Volume 11, 5813-5819.	1.9	1
470	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Current Medical Research and Opinion, 2019, 35, 1761-1767.	1.9	1
471	A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1503.	2.8	1
472	Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. Journal of Thoracic Oncology, 2021, 16, e12-e14.	1.1	1
473	Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations. Journal of Thoracic Oncology, 2021, 16, 712-714.	1.1	1
474	MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.. Journal of Clinical Oncology, 2014, 32, e19047-e19047.	1.6	1
475	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. Journal of Clinical Oncology, 2018, 36, 9077-9077.	1.6	1
476	Predictive value of intra-tumoural TCRÎ² rearrangements in precisely selecting adjuvant therapy for EGFR-mutant non-small-cell lung cancer. Clinical and Translational Discovery, 2022, 2, .	0.5	1
477	Safety and Efficacy of Epatinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study. Clinical Lung Cancer, 2022, 23, e353-e361.	2.6	1
478	Percutaneous superfine-needle aspiration biopsy of intrathoracic lesions guided by simulator. Journal of Surgical Oncology, 1989, 40, 135-138.	1.7	0
479	Subaortic Blind Mitral Pouch in a Double-Inlet Right Ventricle. Thoracic and Cardiovascular Surgeon, 1994, 42, 315-317.	1.0	0
480	Transdermal Fentanyl for Management of Cancer Pain in Elderly Patients in China. Chinese-German Journal of Clinical Oncology, 2004, 3, 85.	0.1	0
481	Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients. Chinese-German Journal of Clinical Oncology, 2008, 7, 677-681.	0.1	0
482	Mutation and polymorphism in the tyrosine kinase domain of KDR in Chinese human lung cancer patients. Chinese-German Journal of Clinical Oncology, 2009, 8, 309-313.	0.1	0
483	Misuse of Pirated Drugs: Why China? What Is Next?. Journal of Global Oncology, 2016, 2, 440-441.	0.5	0
484	CSCO joins ESMO Open-Cancer Horizons. ESMO Open, 2016, 1, e000120.	4.5	0
485	Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study. Journal of Thoracic Oncology, 2017, 12, e5-e6.	1.1	0
486	Reply to L. Zeng et al. Journal of Clinical Oncology, 2018, 36, 3177-3178.	1.6	0

#	ARTICLE	IF	CITATIONS
487	Adjuvant TKIs: still an optimal choice. Journal of Thoracic Disease, 2018, 10, E812-E814.	1.4	0
488	Personalized adjuvant treatment: go through the past to the future. Journal of Thoracic Disease, 2019, 11, E109-E111.	1.4	0
489	The superstars of precision medicine—EGFR inhibitors in adjuvant treatment of lung cancer. Journal of Thoracic Disease, 2019, 11, E11-E13.	1.4	0
490	Reply to A. Tateishi et al. Journal of Clinical Oncology, 2020, 38, 286-287.	1.6	0
491	Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author's reply. Translational Lung Cancer Research, 2020, 9, 160-162.	2.8	0
492	The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncology, 2021, 17, 783-794.	2.4	0
493	Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical Drug Investigation, 2021, 41, 483-488.	2.2	0
494	Pseudopathologic vertebral body enhancement. Cleveland Clinic Journal of Medicine, 2021, 88, 424-425.	1.3	0
495	ZD1839 for the treatment of heavily pretreated non-small cell lung cancer. Journal of Clinical Oncology, 2004, 22, 7341-7341.	1.6	0
496	Lung Cancer Targeted Therapy. , 2011, , 2111-2115.		0
497	Lung Cancer Targeted Therapy. , 2015, , 1-5.		0
498	ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9062-9062.	1.6	0
499	Lung Cancer Targeted Therapy. , 2017, , 2591-2595.		0
500	What's new in the treatment of advanced small-cell lung cancer. Translational Cancer Research, 2017, 6, 639-644.	1.0	0
501	A dedicated lung cancer immunotherapy outpatient clinic: The first experience in China.. Journal of Clinical Oncology, 2020, 38, e14022-e14022.	1.6	0
502	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with EGFR-m+ non-small-cell lung cancer. Future Oncology, 2022, 18, 1485-1497.	2.4	0
503	Phase I/IIb dose-escalation study of avelumab in Chinese patients with advanced solid tumors. Future Oncology, 2022, , .	2.4	0
504	A Novel Radiopathological Grading System to Tailor Recurrence Risk for Pathologic Stage IA Lung Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
505	Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations. JTO Clinical and Research Reports, 2022, 3, 100348.	1.1	0